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Incubation of big endothelin-3 (bi_~ ET-3;.4~) with the membrane fraction obtained from cultured endothelial cells (ECs) resulted in an increase 
in immanoreactive-l:T (IR-ET), This in,reusing activity was markedl:¢ suppressed by phosphoramidon, which is known to inhibit he conversion 
of big ETA ~-39 to ET-I ~-~t. Reverse.phase HPLC of the incubation mixture of the membrane fraction with big ET-3 revealed one major 1R-ET 
component corresponding to the elution position of synthetic ET-3~.2~. When tile cultured Ees were incubated with big ET-3, a conversion to the 
mature ET-3, as well as an endogenous ET-I generation, was observed. Both responses were markedly suppressed by phosphoramidon. By the 
gel filtration of0.5% CHAPS-solubilized fraction of membrane pellets of ECs, the molecular mass of the proteinase which converts big ET-I and 
bi/~ ET-3 to their mature form was estimated to be 300-350 kDa. Phosphoramidon almost c:ompletely abolished both converting activities of the 
proteinase. We conclude that the above type of phosphoramidon-sensitive metalloproteinase functions as an F-T-converting enzyme to generate 
the mature form from big ET-I and big ET-3 in ECs, 
Endothelin-l; Endothelin-3; Big endothelin-l; Big endothelin-3; Metalloproteinase; Phosphoramidon 
1. INTRODUCTION 
Endothelin-I (ET-11_~) is produced from a 39-amino 
acid inactive intermediate form, termed big ET-lt_39, 
through unusual proteolytic processing at the Trp -~- 
Val +'+" bond by a putative ET-converting enzyme (ECE) 
[1]. We have proposed that the phosphoramidon-sensi- 
tire metalloprotcinase is the most plausible candidate 
for ECE in vascular endothelial cells (ECs) [2-5] and 
smooth muscle cells [6]. Findings that the pressor activ- 
ity of big ET-I (probably by conversion to ET-1) is 
effectively suppressed by phosphoramidon [7-10], 
strongly support a functional role of the above t~ype oP 
proteinase as a physiologically relevant ECE. 
Subsequent to the original discovery of ET-I [1], an 
analysis of a human genomie library showed the possi- 
ble existence oi' three structurally distinct isopeptides, 
termed ET-1, ET-2 and ET-3 [1 I]. Several studies have 
indicated the presence of immunoreactive (IR)-ET-!, 
IR-ET-2 and IR-ET-3 in mammalian tissues [12-14]. 
Based on findings that ET-2 and ET-3 are derived from 
big ET-2j_~7 and big ET-3~j, as deduced from sequence 
analyses of eDNA [15-17], one can speculate on the 
possible biosynthetic pathway for ET-2 and ET-3 anal. 
ogous to ET-1. 
We report here that the phosphoramidon-sensitive 
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and membrane-bound metalloproteinase derived from 
cultured porcine aortic ECs, of which the molecular 
mass is estimated to be 300-350 kDa, can convert both 
big ET-1 and big ET-3 to their mature form. 
2. MATERIALS AND METHODS 
2.1. Materials 
ET-I 1-21, ET-31_:t, porcine big ET.I ~-~9, human bi~ ET-3~_41(amide) 
and phosphoramidon were purchased from Peptide Institute Inc. 
(Osaka, Japan). [~I]ET-1 and [t"~I]ET-3 were obtained from Amer- 
sham, Japan. 
2,9, Cell culture attd preparation of membrane fi'actlon 
ECs isolated from fresh porcine aortas were cultured as described 
[18,19], and used betwee.n, the 5th and 10th passages. To obtain the 
membrane fraction of ECs, the confluent cells were scraped with a Cell 
Lil'ter (Costar, MA), Alter washing with phosphate-buffered saline, 
the cells were homogenized in ice-cold 20 mM Tris.HCl buffer (pH 
7.2) containing 5 mM MgCI,, 0.1 mM E-64 and 0.1 mM p-APMSF, 
and then the preparation was centrifuged at 105,000 x g for 30 rain. 
The pellet was washed with Tris-HCl buffer, r¢~uspended in the same 
buffer and the preparation used as the ,nembrane fraction. For anion. 
exchange HPLC and gel filtration I-IPLC, the membrane pellet wa~ 
resuspended in the Tris-HCl buffer containing 0.5% CHAPS. After 36 
h, the suspension was centrifuged at 105,000 x g for 30 min, and the 
r~sultin8 supernatant served for I-tPLC. In some experiments, the 
cultured intact ECs grown in 60-ram gelatin.coated Petri dishes were 
incubated with 3 ml of serum-free Dulbeceo's modified Eagle's me- 
dium containing 0.01% heat-inactivated bovine serum albumin, in the 
absence or presence of phosphoramidon (10 "4 M) and big ET-3 (70 
pmol), at 37°C in a CO2 incubator for 12 h. After the incubation, ETs 
in the medium were extraet~ with a Sep-Pak C;, cartridge (Waters, 
MA), as described [3]. The eluates were subjected to reverse-phase 
(RP)-I-IPLC coupled with a radioimmunoa~ay (RIA) for ETs, 
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2.3. Anion.exchange HPLC 
Dctergent-solubilized fractions (about 6mg of protein) of the mem- 
brane pellet derived from about 7.5 × 107 cells were applied to a 
COSMOGEL QA column (8 x 75 mm. Nakalai Tesqu¢ Ltd., Kyoto, 
Japan) using a Waters HPLC system (Model 650E). Elution was 
performed in the same manner as described [4], except hat the buffer 
contained 0,5% CHAPS, Active fractions were subj~ted to a gel 
filtration HPLC. 
2,4, Gel filtrattan HPLC 
A Superdex 200 pg (Hiload 16/60, Pharmacia) was used to estimate 
the molecular weight of ECE, The column was eluted with 20 mM 
Tris-HCl buffer (pH 7,2) containing 0,2 M NaCl and 0.5% n.oetyl.p- 
n-thioglu¢osid¢, The flow rate was 1 ml/min and 1 ml fractions were 
collected, 
2.5. Measurenlent of ET.converting activity 
ET-converting activities of the membrane fraction of ECs and those 
preach fraction from anion.exchange HPLC and gel filtration HPLC 
were determined as d~cribed [2], 50/al of the sample and 0,05 ml of 
enzyme inhibitor solution were mixed with 0,35 ml of 50 mM sodium 
phosphate buffer (pH 6.5). After pre.incubation at 370C for 30 rain. 
0.05 ml of big ET-I or big ET-3 (final concentrations: 100 ng big 
ET-I/ml; 112 ng big ET-3/ml) was added to tile mixture and the 
preparation was incubated at 37°C for 0,5-12 h, The reaction was 
stopped by boiling for 10 rain, The sample were neutralized and 
centrifuged at 8,000 × g for 5 mix. The resulting supematant was used 
for the RIA and RP-HPLC. 
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Fig. 1. Time-course ofthe increase in IR-ET during incubation ofbig 
ET-I with the membrane fraction of cultured ECs (derived from 4 x 
10 ~ cells). Incubation was performed with I mM .,V-ethylmaleimide. n 
the presence or absence of 0,1 mM phosphoramidon. Values represent 
the mean _ S,E.M. fl'om four separate xperiments. 
2,6, Radioimnlunoassay ( RIA ) 
RIAs for ET-I and ET-3 were performed as described [18,19]. ET-I 
antiserum (a generous gift from Dr. M.R. Brown, Department of
Medicine, University of California, San Diego) had a 50% cross- 
reactivity with ET-3 and no cross-reactivity with big ET-1 and big 
ET-3. 
2,7. Reverse.phase (RP)-HPLC 
RP-HPLC was performed using a Capccll-Pak 5C~a-SG300 column 
(4.6 × 250 ram, Shlseido, Tokyo, Japan) ¢luted with a linear gradient 
from 0 to 35% CH.~CN in 0,02% TFA for i 5 rain, followed by isocratie 
elution at 35% CH.~CN in 0.02% TFA for 15 rain and a linear gradient 
from 35 to 63% CH~CN in 0.02% TFA for 15 mix. The flow rate was 
0.5 ml/min, Each fraction was evaporated and assayed for IR-ET 
using RIA. 
3. RESULTS AND DISCUSSION 
When big ET-1 was incubated with the membrane 
fraction of cultured ECs at pH 6.5, a time-dependent 
increase in IR-ET in the reaction mixture was observed 
(Fig. 1). This increasing response was markedly inhib- 
ited by phosphoramidon, as described [2,4]. In addition, 
we have already confirmed by RP-HPLC that the major 
IR-ET component is ET-1 converted from big ET-1 [2]. 
Incubation of big leT-3 with the membrane fraction also 
increased IR-ET in a time-dependent manner (Fig. 2). 
The optimum pH of this increase was 6.5, which is the 
same value seen with big ET-I as a substrate [2]. In the 
presence of 10 -4 M phosphoramidon there was no nota- 
ble increase in IR-ET. 
Using RP-HPLC coupled with RIA for ET, we char- 
acterizcd the IR-ET in the reaction mixture of big ET-3 
with the membrane fraction. The elution profiles re- 
vealed one major IR-ET component corresponding to 
the elution position of synthetic ET-3 (Fig. 3A). The 
addition of phosphoramidon to the reaction mixture 
greatly decreased the production of ET-3-1ike materials 
(Fig. 3B). 
As described [3,5], cultured ECs release ET-I in a 
time-dependent manner, and the amount of ET-I is 
remarkably decreased by phosphoramidon and accom- 
panied by an increase in the release of big ET-1, thereby 
strongly suggesting that phosphoramidon suppresses 
the release of ET-1 from ECs by inhibiting ECE. In the 
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Fig. 2. Time-course ofthe increase in IR-ET during incubation ofbig 
ET-3 with the membrane fraction of cultured ECs (derived from 4 x 
l0 s cells). Incubation was performed with 1 mM N-ethylmaleimide. in 
the presence or absence of 0.1 mM phosphoramidon. Valu~ represent 
tile mean :t: S.E.M. from four ~parat¢ experiment, 
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Fig, 3. RP-HPLC profiles of  IR-ET in the reaction mixture of big ET-3 
with the membrane fraction, Th¢ incubation wag carried out at pH 6.5 
for 6 h with 1 mM N.ethylmaleimide. A, without phosphoramidon; 
B, with 0.1 mM phosphoramidon. The arrow indicates the elution 
position of synthetic ET-3. 
present study, when the intact cultured cells were incu- 
bated with big ET-3 (70 pmol/106 cells) for 12 h, there 
was a gradual additional increase in IR-ET in the cul- 
ture medium (data not shown). Consistent with the case 
of endogenous IR-ET release (derived from ET-1), 
phosphoramidon markedly suppressed the IR-ET in- 
crease by the exogenous application of big ET-3. Using 
RP-HPLC and RIA, we examined the IR-ET in the 
culture medium with exogenous big ET-3 application. 
As shown in Fig. 4A, there were two major components 
of IR-ET, which corresponded to elution positions of 
synthetic ET-I and ET-3, respectively, thereby indicat- 
ing that the additional increase in IR-ET by exogenous 
big ET-3 application isdue to production of the mature 
ET-3. Phosphoramidon potently suppressed this ET-3 
production, as it did the endogenous ETA production 
(Fig. 4B). 
We further characterized the phosphoramidon-sensi- 
rive ECE solubilized from the membrane fraction of 
ECs, using anion-exchange HPLC and gel filtration 
HPLC. The anion-exchange HPLC of the detergent- 
solubillzed fraction gave one major peak of big ET-1- 
converting activity in the eluate at 0.2 M NaCL Qualita- 
tively similar elution patterns were observed with big 
ET-3-converting activity (data not shown). Active frac- 
tions obtained from anion-exchange HPLC were ap- 
plied to a Superdex 200 pg column in order to estimate 
the molecular weight of the enzyme. As shown in Fig. 
5 (upper panel), the big ET-1 converting activity was 
observed as a single major peak ,-,r~d corresponded to an 
apparent molecular mass of 300-350 kDa. The addition 
of phosphoramidon abolished the converting activity in 
the peak fraction, although phosphoramidon-resistant 
small activities were detected in later fractions. 
Phosphoramidon-sensitive big ET-3-converting activity 
was also observed as a single major peak in the same 
fractions as seen with big ET-I converting activity (Fig. 
5, lower panel). 
There is accumulating evidence that big ET-1 is con- 
verted to ET-I in various cells and tissues by phospho- 
ramidon-sensitive metalloproteinase [2-6,20-27]. On 
the other hand, results with regard to the conversion of 
big ET-3 are conflicting. Okada et al. [20] reported that 
a membrane-bound and phosphoramidon-sensitive ET- 
I converting enzyme of cultured bovine ECs is much 
less susceptible to big ET-3. Takada et al. [28] also 
found no substantial big ET-3-converting activity of 
cytosolic ET-l-converting enzyme obtained from cul- 
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FiB, 4. RP-HPLC profiles of IR-ET in culture medium of ECs. £Cs 
were incubated with synthetic big ET-3 for 12 h, in the absence (A) 
or presence (B) of 0.1 raM phosphoramidon. Arrows indicate the 
¢lution position of synthetic ET-I and ET-3. 
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Fig. 5, Elution profiles of phosphoramidon.sensitive ECE by gel filtra- 
tion on a Superdex 200 pg column, Each eluate was incubated with 
big ET-I or big ET-3 in the presence of I mM N-ethylmaleimide for 
12 h. Arrows indicate the elation positions of void volume (Vo) and 
molecular weight standards: 1, thyroglobulin (669 kDa); 2, ferritin 
(440 kDa); 3, catala.~ (232 kDa); 4, bovine scram albumin (67 kDa). 
with tl, e findings of Ohnaka et al. [30] and ours, the 
phosphoramidon-sensitive metaUoprot¢inas¢ appears 
to be involved at lea~t in the extraccllular conversion of 
big ET-3 to the mature form. The reason for the discrep- 
ancy between our findings and those previously pub- 
lished is unclear but may be partly due to differences in
species and experimental conditions. 
In the present study, we characterized for the first 
time the big ET-3.converting en~me in ECs. The re- 
subs clearly indicate that cultured porcine ECs contain 
phosphorarnidon-sensitive m talloprot¢inas¢ which 
converts big ET-3 to ET-3, as seen in the ease of the 
conversion of big ET-I in the same cells. Thus, big 
ET-3, as well as big ET-I, is a good substrat¢ for 
phosphoramidon-sensitiv¢ ECE in ECs. Taken together 
with the chromatographic analysis, we conclud~ that 
the phosphoramidon-scnsitive ECE with an apparent 
molecular weight of 300-350 kDa can convert both big 
ET-1 and big ET-3 to their mature form. 
A possible relationship between an accelerated for- 
mation of ET-1 and various vascular diseases has been 
proposed [31,32]. Thus, a specific inhibitor of ECE may 
have beneficial effects in the prevention and/or treat- 
ment of certain diseases. Most recently, we found that 
intracisternal dministration f phosphoramidon effec- 
tively suppressed the development of cerebral vase- 
spasm tbllowing subarachnoid hemorrhage in the ca- 
nine 'two-hemorrhage' model and suggested that ET-1 
may be a causal factor in the cerebral vasospasm [33]. 
The pathophysiological significance of ET-3 remains 
the subject of ongoing studies. 
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tured bovine ECs. Moreover, D'Orl6ans-Juste etal. [29] 
found that, unlike big ET-1, big ET-3 induced no pres- 
ser responses in anesthetized guinea-pigs, thereby sug- 
gesting that ECE is specific for big ET-1 and may not 
convert big ET-3 to the mature form. In contrast, using 
intact cultured bovine ECs, Ohnaka et al. [30] noted 
that exogenously applied big ET-3 is converted to the 
mature ET-3 at a high affinity and that this conversion 
is abolished by phosphoramidon, i  the same manner 
as seen with big ET-I. Most recently, we noted that 
intravenous injection of big ET-3 (3 nmol/kg) to anes- 
thetized rats produced a long-lasting hypertensive ef- 
fect, although the magnitude was slightly less potent 
than that of big ET-I. The presser response to big ET-3 
was markedly attenuated by the pretreatment with 
phosphoramidon (5 mg/kg, i.e.), thereby suggesting 
that big ET-3 is converted to biologically active ET-3 
by phosphoramidon-sensitive m talloproteinas¢ in
viva, in the same manner as the case seen with big ET-1 
(Matsumura et al., submitted). Thus, taken together 
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